Star Therapeutics Unveils Clinical Findings on VGA039, an Injectable Therapy for Von Willebrand Disease (VWD).

Arrowhead Pharmaceuticals to Progress RNAi Therapy Plozasiran into Phase 3 CAPITAN Trial for Cardiovascular Results.

Werewolf Therapeutics Presents Early Safety and Effectiveness Results from Phase 1 Study of WTX-330 in Patients with Advanced Solid Tumors or Non-Hodgkin Lymphoma.

EZHARMIA® Receives Approval in Japan as the First Dual EZH1 and EZH2 Blocker for Peripheral T-Cell Lymphoma Therapy.

vTv Therapeutics Announces Enrollment of First Participant in CATT1 Key Study for Cadisegliatin in Type 1 Diabetes.

TiumBio Unveils Promising Initial Clinical Data for TU7710, Its Hemophilia Therapy Candidate, at ISTH 2024.

The Phase 3 FLOW study presented at the 84th ADA Scientific Sessions showed a 1 mg dose of Ozempic® (semaglutide) injection decreased the risk of kidney disease-related events.

Innovent Unveils Phase 3 Study Outcomes of Mazdutide for Weight Control at the ADA's 84th Scientific Sessions.

The European Commission has approved Roche's OCREVUS for subcutaneous use, making it the first and only twice-yearly injection for relapsing and primary progressive multiple sclerosis.

Alnylam Announces Successful Topline Results from HELIOS-B Phase 3 Trial of Vutrisiran, Showing Statistical Significance in Primary and All Secondary Endpoints in Both Combined and Monotherapy Groups.

This IND will enable the assessment of ADI-270, for the therapeutic intervention in relapsed/refractory renal cell carcinoma.

Scholar Rock Unveils New SRK-439 Preclinical Data Showing Notable Lean Mass Preservation and Reduced Fat Mass Rebound After Stopping GLP-1 Receptor Agonist.